A detailed history of Vanguard Group Inc transactions in Mi Nk Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 234,182 shares of INKT stock, worth $168,611. This represents 0.0% of its overall portfolio holdings.

Number of Shares
234,182
Previous 234,182 -0.0%
Holding current value
$168,611
Previous $222,000 21.17%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$1.1 - $2.09 $7,701 - $14,632
-7,001 Reduced 2.9%
234,182 $257,000
Q2 2023

Aug 14, 2023

BUY
$0.89 - $3.33 $170,947 - $639,613
192,076 Added 391.14%
241,183 $506,000
Q3 2022

Nov 14, 2022

BUY
$1.19 - $3.4 $58,437 - $166,963
49,107 New
49,107 $104,000
Q2 2022

Aug 12, 2022

SELL
$1.25 - $3.25 $12,935 - $33,631
-10,348 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$2.2 - $4.75 $930 - $2,009
-423 Reduced 3.93%
10,348 $23,000
Q4 2021

Feb 14, 2022

BUY
$4.12 - $20.03 $44,376 - $215,743
10,771 New
10,771 $48,000

Others Institutions Holding INKT

About MiNK Therapeutics, Inc.


  • Ticker INKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,775,100
  • Market Cap $24.3M
  • Description
  • MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...
More about INKT
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.